Research ExplorerPublicationsThe independent prognostic impact of the GATA2 pioneering fa...

The independent prognostic impact of the GATA2 pioneering factor is restricted to ERG-negative prostate cancer

Standard

The independent prognostic impact of the GATA2 pioneering factor is restricted to ERG-negative prostate cancer. / Büscheck, Franziska; Zub, Maciej; Heumann, Asmus; Hube-Magg, Claudia; Simon, Ronald; Lang, Dagmar S; Höflmayer, Doris; Neubauer, Emily; Jacobsen, Frank; Hinsch, Andrea; Luebke, Andreas M; Tsourlakis, Maria Christina; Sauter, Guido; Huland, Hartwig; Graefen, Markus; Haese, Alexander; Heinzer, Hans; Schlomm, Torsten; Clauditz, Till S; Burandt, Eike; Wilczak, Waldemar; Steurer, Stefan; Minner, Sarah.

In: TUMOR BIOL, Vol. 41, No. 7, 07.2019, p. 1010428318824815.

Research output: SCORING: Contribution to journal › SCORING: Journal article › Research › peer-review

Harvard

Büscheck, F, Zub, M, Heumann, A, Hube-Magg, C, Simon, R, Lang, DS, Höflmayer, D, Neubauer, E, Jacobsen, F, Hinsch, A, Luebke, AM, Tsourlakis, MC, Sauter, G, Huland, H, Graefen, M, Haese, A, Heinzer, H, Schlomm, T, Clauditz, TS, Burandt, E, Wilczak, W, Steurer, S & Minner, S 2019, 'The independent prognostic impact of the GATA2 pioneering factor is restricted to ERG-negative prostate cancer', TUMOR BIOL, vol. 41, no. 7, pp. 1010428318824815. https://doi.org/10.1177/1010428318824815

APA

Büscheck, F., Zub, M., Heumann, A., Hube-Magg, C., Simon, R., Lang, D. S., Höflmayer, D., Neubauer, E., Jacobsen, F., Hinsch, A., Luebke, A. M., Tsourlakis, M. C., Sauter, G., Huland, H., Graefen, M., Haese, A., Heinzer, H., Schlomm, T., Clauditz, T. S., ... Minner, S. (2019). The independent prognostic impact of the GATA2 pioneering factor is restricted to ERG-negative prostate cancer. TUMOR BIOL, 41(7), 1010428318824815. https://doi.org/10.1177/1010428318824815

Vancouver

Büscheck F, Zub M, Heumann A, Hube-Magg C, Simon R, Lang DS et al. The independent prognostic impact of the GATA2 pioneering factor is restricted to ERG-negative prostate cancer. TUMOR BIOL. 2019 Jul;41(7):1010428318824815. https://doi.org/10.1177/1010428318824815

Bibtex

@article{2f5ca77e3f5141ae90c4ed0d648c7c9d,
title = "The independent prognostic impact of the GATA2 pioneering factor is restricted to ERG-negative prostate cancer",
abstract = "GATA2 is a pioneering transcription factor governing androgen receptor expression and signaling in prostate cells. To understand the prognostic potential of GATA2 assessment in prostate cancer, we analyzed nuclear GATA2 expression on an annotated tissue microarray with 12,427 prostate cancer samples. Normal prostate glands were negative to weakly positive. GATA2 staining was found in almost all prostate cancers (95%). Strong GATA2 staining was linked to advanced tumor stage, high classical and quantitative Gleason grade (p < 0.0001 each), positive nodal stage (p = 0.0116), and early biochemical recurrence (p < 0.0001). GATA2 was linked to ERG-fusion-type cancers, with strong GATA2 staining in 29% of ERG-negative and 53% of ERG-positive cancers (p < 0.0001). Separate calculations in 3854 cancers with and 4768 cancers without TMPRSS2:ERG fusion revealed that these associations with tumor phenotype and patient outcome were largely driven by the subset of ERG-negative tumors. GATA2 expression was further linked to androgen receptor expression: Only 8% of androgen receptor-negative, but 56% of strongly androgen receptor expressing cancers had strong GATA2 expression (p < 0.0001). In conclusion, the results of our study demonstrate that increasing GATA2 levels are linked to prostate cancer progression and aggressiveness. The prognostic value of GATA2 is remarkable in ERG-negative cancers. However, the upregulation of GATA2 in ERG-positive cancers makes it unsuitable as a prognostic marker in this patient subset.",
keywords = "Adult, Aged, Disease Progression, Disease-Free Survival, Follow-Up Studies, GATA2 Transcription Factor/metabolism, Humans, Kaplan-Meier Estimate, Lymphatic Metastasis, Male, Middle Aged, Multivariate Analysis, Neoplasm Invasiveness, Neoplasm Recurrence, Local, Phenotype, Prognosis, Prostatectomy, Prostatic Neoplasms/diagnosis, Receptors, Androgen/metabolism, Tissue Array Analysis, Transcriptional Regulator ERG/metabolism, Treatment Outcome",
author = "Franziska B{\"u}scheck and Maciej Zub and Asmus Heumann and Claudia Hube-Magg and Ronald Simon and Lang, {Dagmar S} and Doris H{\"o}flmayer and Emily Neubauer and Frank Jacobsen and Andrea Hinsch and Luebke, {Andreas M} and Tsourlakis, {Maria Christina} and Guido Sauter and Hartwig Huland and Markus Graefen and Alexander Haese and Hans Heinzer and Torsten Schlomm and Clauditz, {Till S} and Eike Burandt and Waldemar Wilczak and Stefan Steurer and Sarah Minner",
year = "2019",
month = jul,
doi = "10.1177/1010428318824815",
language = "English",
volume = "41",
pages = "1010428318824815",
journal = "TUMOR BIOL",
issn = "1010-4283",
publisher = "Springer Netherlands",
number = "7",

}

RIS

TY - JOUR

T1 - The independent prognostic impact of the GATA2 pioneering factor is restricted to ERG-negative prostate cancer

AU - Büscheck, Franziska

AU - Zub, Maciej

AU - Heumann, Asmus

AU - Hube-Magg, Claudia

AU - Simon, Ronald

AU - Lang, Dagmar S

AU - Höflmayer, Doris

AU - Neubauer, Emily

AU - Jacobsen, Frank

AU - Hinsch, Andrea

AU - Luebke, Andreas M

AU - Tsourlakis, Maria Christina

AU - Sauter, Guido

AU - Huland, Hartwig

AU - Graefen, Markus

AU - Haese, Alexander

AU - Heinzer, Hans

AU - Schlomm, Torsten

AU - Clauditz, Till S

AU - Burandt, Eike

AU - Wilczak, Waldemar

AU - Steurer, Stefan

AU - Minner, Sarah

PY - 2019/7

Y1 - 2019/7

N2 - GATA2 is a pioneering transcription factor governing androgen receptor expression and signaling in prostate cells. To understand the prognostic potential of GATA2 assessment in prostate cancer, we analyzed nuclear GATA2 expression on an annotated tissue microarray with 12,427 prostate cancer samples. Normal prostate glands were negative to weakly positive. GATA2 staining was found in almost all prostate cancers (95%). Strong GATA2 staining was linked to advanced tumor stage, high classical and quantitative Gleason grade (p < 0.0001 each), positive nodal stage (p = 0.0116), and early biochemical recurrence (p < 0.0001). GATA2 was linked to ERG-fusion-type cancers, with strong GATA2 staining in 29% of ERG-negative and 53% of ERG-positive cancers (p < 0.0001). Separate calculations in 3854 cancers with and 4768 cancers without TMPRSS2:ERG fusion revealed that these associations with tumor phenotype and patient outcome were largely driven by the subset of ERG-negative tumors. GATA2 expression was further linked to androgen receptor expression: Only 8% of androgen receptor-negative, but 56% of strongly androgen receptor expressing cancers had strong GATA2 expression (p < 0.0001). In conclusion, the results of our study demonstrate that increasing GATA2 levels are linked to prostate cancer progression and aggressiveness. The prognostic value of GATA2 is remarkable in ERG-negative cancers. However, the upregulation of GATA2 in ERG-positive cancers makes it unsuitable as a prognostic marker in this patient subset.

AB - GATA2 is a pioneering transcription factor governing androgen receptor expression and signaling in prostate cells. To understand the prognostic potential of GATA2 assessment in prostate cancer, we analyzed nuclear GATA2 expression on an annotated tissue microarray with 12,427 prostate cancer samples. Normal prostate glands were negative to weakly positive. GATA2 staining was found in almost all prostate cancers (95%). Strong GATA2 staining was linked to advanced tumor stage, high classical and quantitative Gleason grade (p < 0.0001 each), positive nodal stage (p = 0.0116), and early biochemical recurrence (p < 0.0001). GATA2 was linked to ERG-fusion-type cancers, with strong GATA2 staining in 29% of ERG-negative and 53% of ERG-positive cancers (p < 0.0001). Separate calculations in 3854 cancers with and 4768 cancers without TMPRSS2:ERG fusion revealed that these associations with tumor phenotype and patient outcome were largely driven by the subset of ERG-negative tumors. GATA2 expression was further linked to androgen receptor expression: Only 8% of androgen receptor-negative, but 56% of strongly androgen receptor expressing cancers had strong GATA2 expression (p < 0.0001). In conclusion, the results of our study demonstrate that increasing GATA2 levels are linked to prostate cancer progression and aggressiveness. The prognostic value of GATA2 is remarkable in ERG-negative cancers. However, the upregulation of GATA2 in ERG-positive cancers makes it unsuitable as a prognostic marker in this patient subset.

KW - Adult

KW - Aged

KW - Disease Progression

KW - Disease-Free Survival

KW - Follow-Up Studies

KW - GATA2 Transcription Factor/metabolism

KW - Humans

KW - Kaplan-Meier Estimate

KW - Lymphatic Metastasis

KW - Male

KW - Middle Aged

KW - Multivariate Analysis

KW - Neoplasm Invasiveness

KW - Neoplasm Recurrence, Local

KW - Phenotype

KW - Prognosis

KW - Prostatectomy

KW - Prostatic Neoplasms/diagnosis

KW - Receptors, Androgen/metabolism

KW - Tissue Array Analysis

KW - Transcriptional Regulator ERG/metabolism

KW - Treatment Outcome

U2 - 10.1177/1010428318824815

DO - 10.1177/1010428318824815

M3 - SCORING: Journal article

C2 - 31296150

VL - 41

SP - 1010428318824815

JO - TUMOR BIOL

JF - TUMOR BIOL

SN - 1010-4283

IS - 7

ER -